UPDATE - Oppenheimer Initiates Coverage on Coronado Biosciences (CNDO) with an Outperform; Harnessing Nature to Treat Disease and Cancer
CNDO Hot Sheet
Rating Summary:2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
UPDATE - Oppenheimer initiates coverage on Coronado Biosciences (NASDAQ: CNDO) with an Outperform. PT $12.00.
Oppenheimer analyst said, "Coronado's leading asset (CNDO-201) is a pharmaceutical formulation of porcine parasite for the treatment of human autoimmune disease. Although the therapy is unconventional, it aims to recreate a natural relationship that humans have had with intestinal parasites throughout the millenia until the significant public health changes in the last century. The treatment showed encouraging efficacy in Crohn's disease and ulcerative colitis, as well as early data in multiple sclerosis. We believe that the market is largely overlooking Coronado due to the unconventional approach of its leading asset. We anticipate investors to discover this company, particularly as new CNDO-201 data is presented in 2H12."
To see more ratings on CNDO, Click Here
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
Oppenheimer analyst said, "Coronado's leading asset (CNDO-201) is a pharmaceutical formulation of porcine parasite for the treatment of human autoimmune disease. Although the therapy is unconventional, it aims to recreate a natural relationship that humans have had with intestinal parasites throughout the millenia until the significant public health changes in the last century. The treatment showed encouraging efficacy in Crohn's disease and ulcerative colitis, as well as early data in multiple sclerosis. We believe that the market is largely overlooking Coronado due to the unconventional approach of its leading asset. We anticipate investors to discover this company, particularly as new CNDO-201 data is presented in 2H12."
To see more ratings on CNDO, Click Here
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Goldman Sachs Boosts Numbers on PVH Corp (PVH) After Q1 Beat
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
